Wealthfront Advisers Sells 6,410 Shares of Amgen Amid Strong Performance
Wealthfront Advisers LLC has sold 6,410 shares of Amgen Inc. stock in the second quarter, reducing its position by 7.1%. The company now owns 84,152 shares worth $30,473,000 at the end of the most recent quarter.
According to a 13F filing with the Securities & Exchange Commission, Wealthfront Advisers LLC has trimmed its stake in Amgen despite the company's strong performance. In fact, Amgen was highlighted as one of the best-performing U.S. large-cap drugmakers in 2026, outperforming peers Merck and Pfizer.
The medical research company has seen its stock price surge due to healthcare-sector strength and a rotation toward profitable drugmakers. Additionally, renewed enthusiasm for biotechnology has improved sentiment across the industry.
Amgen's latest quarterly results beat consensus estimates for earnings and revenue, with revenue growth accelerating year over year. The company has set its FY 2026 guidance at $22.300-23.500 EPS, and analysts expect it to post $22.78 EPS for the current year.